The DOI matches its Crossref record; 229 of the 229 references it cites were found in a registry or an index.
Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives
Open accessAbstract
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide. NAFLD begins as a relatively benign hepatic steatosis which can evolve to non-alcoholic steatohepatitis (NASH); the risk of cirrhosis and hepatocellular carcinoma (HCC) increases when fibrosis is present. NAFLD represents a complex process implicating numerous factors—genetic, metabolic, and dietary—intertwined in a multi-hit etiopathogenetic model. Recent data have highlighted the role of gut dysbiosis, which may render the bowel more permeable, leading to increased free fatty acid absorption, bacterial migration, and a parallel release of toxic bacterial products, lipopolysaccharide (LPS), and proinflammatory cytokines that initiate and sustain inflammation. Although gut dysbiosis is present in each disease stage, there is currently no single microbial signature to distinguish or predict which patients will evolve from NAFLD to NASH and HCC. Using 16S rRNA sequencing, the majority of patients with NAFLD/NASH exhibit increased numbers of Bacteroidetes and differences in the presence of Firmicutes, resulting in a decreased F/B ratio in most studies. They also present an increased proportion of species belonging to Clostridium, Anaerobacter, Streptococcus, Escherichia, and Lactobacillus, whereas Oscillibacter, Flavonifaractor, Odoribacter, and Alistipes spp. are less prominent. In comparison to healthy controls, patients with NASH show a higher abundance of Proteobacteria, Enterobacteriaceae, and Escherichia spp., while Faecalibacterium prausnitzii and Akkermansia muciniphila are diminished. Children with NAFLD/NASH have a decreased proportion of Oscillospira spp. accompanied by an elevated proportion of Dorea, Blautia, Prevotella copri, and Ruminococcus spp. Gut microbiota composition may vary between population groups and different stages of NAFLD, making any conclusive or causative claims about gut microbiota profiles in NAFLD patients challenging. Moreover, various metabolites may be involved in the pathogenesis of NAFLD, such as short-chain fatty acids, lipopolysaccharide, bile acids, choline and trimethylamine-N-oxide, and ammonia. In this review, we summarize the role of the gut microbiome and metabolites in NAFLD pathogenesis, and we discuss potential preventive and therapeutic interventions related to the gut microbiome, such as the administration of probiotics, prebiotics, synbiotics, antibiotics, and bacteriophages, as well as the contribution of bariatric surgery and fecal microbiota transplantation in the therapeutic armamentarium against NAFLD. Larger and longer-term prospective studies, including well-defined cohorts as well as a multi-omics approach, are required to better identify the associations between the gut microbiome, microbial metabolites, and NAFLD occurrence and progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–229 of 229
Perspectives of Phage Therapy in Non-bacterial Infections
Górski, A., Bollyky, P. L., Przybylski, M., Borysowski, J., Międzybrodzki, R., Jończyk‐Matysiak, E., & Weber‐Dąbrowska, B. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.03306 · Cited by 62
High-fat diet: A trigger of non-alcoholic steatohepatitis? Preliminary findings in obese subjects
Vilar, L. K., de Oliveira, C. P. M. S., Faintuch, J., de Mello, E. S., Nogueira, M. A., dos Santos, T. E., Alves, V. A. F., & Carrilho, F. J. (2008) · Nutrition · doi:10.1016/j.nut.2008.05.017 · Cited by 61
Jadhav, K. S., & Cohen, T. S. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.592157 · Cited by 57
Appleby, R., Moghul, I., Khan, S. A., Yee, M. S., Manousou, P., Neal, T. D., & Walters, J. R. F. (2019) · PLoS ONE · doi:10.1371/journal.pone.0211348 · Cited by 54
Short chain fatty acids induce UCP2-mediated autophagy in hepatic cells
Iannucci, L. F., Sun, J., Singh, B. K., Zhou, J., Kaddai, V., Lanni, A., Yen, P. M., & Sinha, R. A. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.10.072 · Cited by 52
Role of the advanced glycation end products receptor in Crohn’s disease inflammation
Ciccocioppo, R., Vanoli, A., Klersy, C., Imbesi, V., Boccaccio, V., Manca, R., Betti, E., Cangemi, G. C., Strada, E., Besio, R., et al. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i45.8269 · Cited by 50
Chen, J., Zheng, M., Liu, J., Luo, Y., Yang, W., Yang, J., Liu, J., Jingxing, Z., Xu, C., Zhao, F., et al. (2019) · Obesity · doi:10.1002/oby.22627 · Cited by 49
de Medeiros, I. C., & Lima, J. G. (2015) · Medical Hypotheses · doi:10.1016/j.mehy.2015.04.021 · Cited by 47
Hyperammonemia increases sensitivity to LPS
Marini, J. C., & Broussard, S. R. (2006) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2005.12.013 · Cited by 47
Probiotics: achieving a better regulatory fit.
Hoffmann, D. E., Fraser, C. M., Palumbo, F., Ravel, J., Rowthorn, V., & Schwartz, J. (2014) · PubMed · Cited by 46
Ahmad, M. I., Ijaz, M. U., Hussain, M., Haq, I. U., Zhao, D., & Li, C. (2020) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.0c02570 · Cited by 46
Ammonia: A novel target for the treatment of non-alcoholic steatohepatitis
Thomsen, K. L., Chiara, F. D., Rombouts, K., Vilstrup, H., Andreola, F., Mookerjee, R. P., & Jalan, R. (2018) · Medical Hypotheses · doi:10.1016/j.mehy.2018.02.010 · Cited by 43
Petrov, P., García‐Mediavilla, M. V., Guzmán, C., Porras, D., Nistal, E., Martínez‐Flórez, S., Castell, J. V., González‐Gallego, J., Sánchez‐Campos, S., & Jover, R. (2019) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201900487 · Cited by 43
Hodge, A., Lim, S., Goh, E., Wong, O., Marsh, P., Knight, V., Sievert, W., & De Courten, B. (2017) · Nutrients · doi:10.3390/nu9010056 · Cited by 42
Non-alcoholic fatty liver disease causes dissociated changes in metabolic liver functions
Eriksen, P. L., Sørensen, M., Grønbæk, H., Hamilton-Dutoit, S. J., Vilstrup, H., & Thomsen, K. L. (2019) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2019.01.001 · Cited by 39
Cavallari, J. F., Pokrajac, N. T., Zlitni, S., Foley, K. P., Henriksbo, B. D., & Schertzer, J. D. (2020) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00181.2020 · Cited by 39
Faria, S. L., Santos, A., Magro, D. O., Cazzo, E., Assalin, H. B., Guadagnini, D., Vieira, F. T., Dutra, E. S., Saad, M. J. A., & Ito, M. (2020) · Obesity Surgery · doi:10.1007/s11695-020-04956-9 · Cited by 37
Hoozemans, J., de Brauw, M., Nieuwdorp, M., & Gerdes, V. E. A. (2021) · Metabolites · doi:10.3390/metabo11060353 · Cited by 37
Nonalcoholic Fatty Liver Disease
Li, D., Yang, M., Edwards, S., & Ye, S. Q. (2013) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607113481623 · Cited by 35
Steinert, R. E., Rehman, A., Lima, E. S., Agamennone, V., Schuren, F. H. J., Gerö, D., Schreiner, P., Vonlanthen, R., Ismaeil, A., Tzafos, S., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0236936 · Cited by 33
Tabasi, M., Eybpoosh, S., Siadat, S. D., Elyasinia, F., Soroush, A., & Bouzari, S. (2021) · Obesity Surgery · doi:10.1007/s11695-020-05139-2 · Cited by 31
Wu, R., Nakatsu, G., Zhang, X., & Yu, J. Q. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1125883 · Cited by 29
de Sant’Ana, L. P., Ribeiro, D. J. S., Martins, A. M. A., dos Santos, F. N., Corrêa, R., Almeida, R. D. N., Eberlin, M. N., Maurice, C. F., & Magalhães, K. G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02926 · Cited by 27
Vallianou, N. G., Liu, J., & Dalamaga, Μ. (2019) · Metabolism Open · doi:10.1016/j.metop.2019.02.003 · Cited by 26
Self-citationCharacterization of Gut Microbiome in Liver Transplant Recipients With Nonalcoholic Steatohepatitis
Satapathy, S. K., Banerjee, P., Pierre, J. F., Higgins, D., Dutta, S., Heda, R. P., Khan, S. D., Mupparaju, V. K., Mas, V. R., Nair, S. P., et al. (2020) · Transplantation Direct · doi:10.1097/txd.0000000000001033 · Cited by 25
Karami, R., Kermansaravi, M., Pishgahroudsari, M., Talebi, M., Mohammadzadeh, N., & Pazouki, A. (2020) · Updates in Surgery · doi:10.1007/s13304-020-00900-9 · Cited by 24
Armando Rojas, R., González, I., Rodríguez, B. L., Romero, J. A., Figueroa, H., Jorge Llanos, L., Morales, E., & Pérez-Castro, R. (2011) · Microbes and Infection · doi:10.1016/j.micinf.2011.04.005 · Cited by 23
MAFLD: A holistic view to redefining fatty liver disease
Eslam, M., & George, J. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.12.027 · Cited by 20
Circulating bile acid profiles in Japanese patients with NASH
Yara, S., Ikegami, T., Miyazaki, T., Murakami, M., Iwamoto, J., Hirayama, T. T., Kohjima, M., Nakamuta, M., & Honda, A. (2019) · GastroHep · doi:10.1002/ygh2.374 · Cited by 13
Cited by
Mostafavi Abdolmaleky, H., & Zhou, J.-R. (2024) · Antioxidants · doi:10.3390/antiox13080985 · Cited by 286
Buchynskyi, M., Kamyshna, I., Halabitska, I., Petakh, P., Kunduzova, O., Oksenych, V., & Kamyshnyi, O. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1577724 · Cited by 30
Metadata
- Authors
- Vallianou, N., Christodoulatos, G. S., Karampela, I., Tsilingiris, D., Magkos, F., Stratigou, T., Kounatidis, D., & Dalamaga, M.
- Venue
- Biomolecules
- Publisher
- MDPI AG
- Published
- 2021-12-31
- Volume
- 12
- Issue
- 1
- Pages
- 56
- ISSN
- 2218-273X (ISSN-L)
- OpenAlex
- W4205859368
- Cited by
- 289
- References
- 229
- FWCI
- 10.47
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.